

ALASKA MEDICAID  
Prior Authorization Criteria

**Redemplo<sup>®</sup>**  
**(plozasiran)**

**FDA INDICATIONS AND USAGE<sup>1</sup>**

Redemplo<sup>®</sup> is an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

**APPROVAL CRITERIA<sup>1,2,3,4</sup>**

1. Patient meets FDA labeled age **AND**;
2. Prescribed by or in consultation with a cardiologist or endocrinologist **AND**;
3. Patient has the diagnosis of familial chylomicronemia syndrome (FCS) **AND**;
4. One or more of the following applies
  - a. Patient diagnosis confirmed by genetic testing confirmation of biallelic pathogenic variants in FCS-causing genes (e.g. LPL, APOA5, APOC2, LMF1, etc.)
  - b. Moulin score  $\geq 10$
  - c. North American FCS (NAFCS) score  $\geq 45$  **AND**;
5. Patient has tried and failed to demonstrate a response, defined as a reduction in TG levels  $> 20\%$  from baseline to conventional TG lowering therapy (statin, fibrates, etc.) **AND**;
6. Secondary hypertriglyceridemia due to other known sources (chronic kidney disease, uncontrolled diabetes, medication side-effects, etc) has been ruled out **AND**;
7. Provider has attested that patient will be on a low-fat diet concomitantly with Redemplo<sup>®</sup>

**DENIAL CRITERIA<sup>1</sup>**

1. Failure to meet approval criteria **OR**;
2. Patient is currently, or will be taking olezarsen while taking Redemplo<sup>®</sup>

**CAUTIONS<sup>1</sup>**

- While taking Redemplo<sup>®</sup>, the patient's diet should contain  $\geq 20g$  of fat per day, with no more than 15%-20% of daily calories from fat.
- The most common adverse reactions include hyperglycemia, headache, nausea, and injection site reactions.

**DURATION OF APPROVAL**

- Initial Approval: up to 3 months
- Reauthorization Approval: up to 12 months

**QUANTITY LIMIT**

- One 25mg/0.5ml prefilled syringe every 84 days

ALASKA MEDICAID  
Prior Authorization Criteria

**REFERENCES / FOOTNOTES:**

1. Redemplo (plozasiran) [prescribing information]. Pasadena, CA: Arrowhead Inc.; November 2025
2. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. *N Engl J Med.* 2025;392(2):127-137.
3. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an “FCS score.” *Atherosclerosis.* 2018;275:265-272.
4. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol.* 2024;19: 83-94.